SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Taiwan Liposome Company, Ltd. (TLC) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 40/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TLC
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.71
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-24.89
Book Value / Share$0.00
Revenue / Share$2.58
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2011 |
$-14.60 |
$78.23M |
$-216.99M |
-277.4% |
| 2012 |
$-9.50 |
$240.66M |
$-187.13M |
-77.8% |
| 2013 |
$-16.44 |
$158.64M |
$-400.97M |
-252.7% |
| 2014 |
$-23.08 |
$95.92M |
$-632.86M |
-659.8% |
| 2015 |
$-24.50 |
$59.77M |
$-675.69M |
-1130.5% |
| 2016 |
$-29.78 |
$41.67M |
$-824.32M |
-1978% |
| 2017 |
$-31.50 |
$49.64M |
$-873.96M |
-1760.8% |
| 2018 |
$-28.75 |
$62.32M |
$-901.57M |
-1446.6% |
| 2019 |
$-24.64 |
$209.14M |
$-807.52M |
-386.1% |
| 2020 |
$-24.89 |
$101.93M |
$-983.31M |
-964.7% |
